Non-Carcinogenic

Calumet’s custom designed ultra-high pressure hydrotreating unit’s feature multistage processes that overcome the performance and toxicity limitations inherent in older refinery designs. The FDA Ultraviolet Purity Test spectroscopically measures PNA content in the DMSO extract of an oil using the absorbance value at 280-290nm. This test is an industry-accepted predictor of the carcinogenity status of oil and is utillized by Calumet operations as a manufacturing control in the production of our oils to affirm that they are non-carcinogenic.

Modified Ames Test
The Modified Ames Test is a predictor of carcinogenicity in petroleum oils by Modified Salmonella/Microsome Mutation Assay – Calumet oils are regularly evaluated by this analysis.

IP-346
This test measures Polycyclic Aromatics in petroleum fractions. We maintain an IP-346 value of less than 3%.

FDA 21 CFR-178.3620 (c)
Calumet Oils are regularily assessed for this FDA requirement.

International Agency for Research on Cancer (IARC)
Two of the most important references for assessing the carcinogenic potential of a substance have been published by the IARC. All Hydrocal, Calsol 5, Calight and Calpro oils <3000 SUS@100° F are considered Class 4 (severely hydrotreated oils) according to the 1984 IARC Monograph 33; and Group 3 according to the 1987 IARC grouping in their Supplement 7.

ISO 9001:2000 Quality Assurance
Calumet achieved ISO-9002 Certification in 1995 and selected facilities were subsequently registered to QS 9000 in 1999. Calumet continues to maintain their quality systems to today's standards.